Navigation Links
MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
Date:3/30/2011

WARREN, N.J., March 30, 2011 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.  The registration dossier of Montelukast Sodium OSF will be primarily based on pharmacokinetic studies, without the need for clinical efficacy trials.  

Montelukast is the active pharmaceutical ingredient in SINGULAIR, an asthma and allergy treatment that generated full-year worldwide sales of $4.7 billion in 2009 and faces patent expiration in 2012. Montelukast Sodium OSF dissolves within a few seconds when placed on the tongue to provide a complete dose of medication. SINGULAIR is currently approved in a variety of formulations to help control symptoms of asthma and for relief of symptoms of indoor and outdoor allergies, in adults and children 12 months and older.

A. Mark Schobel, President and Chief Executive Officer of MonoSol Rx, stated, "We are pleased with the positive FDA feedback on the 505(b)(2) pathway for Montelukast Sodium OSF, which has demonstrated positive results in pilot bioequivalence studies when compared to SINGULAIR. We envision Montelukast OSF as a competitive product in the $12.7 billion worldwide asthma market, particularly for pediatric patients. Montelukast Sodium OSF provides parents of young children an attractive and convenient alternative to oral granules that must initially dissolve in water, milk or formula.  The OSF formulation also delivers an easy-to-take, taste-masked option for children taking the chewable tablets."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz® (ondansetron) oral soluble film 4 mg and 8 mg, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  (buprenorphine and naloxone) sublingual film 2 mg/0.5 mg and 8 mg/2 mg CIII, the first sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator or other specialty pharma companies that can sell-in and manage product sales and marketing.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs). For existing and future partners, PharmFilm® formulations can also represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  For press releases and other company information visit www.monosolrx.com.

Contacts:

MonoSol Rx:
Keith Kendall
Executive Vice President
(732) 564-5000

The Ruth Group (on behalf of MonoSol Rx)
Jason Rando (media)
(646) 536-7025
jrando@theruthgroup.com

Joshua Drumm (investors)
(646) 536-7006
jdrumm@theruthgroup.com


'/>"/>
SOURCE MonoSol Rx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
2. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
3. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
4. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
5. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
6. Core Essence Secures $11.5 Million Series B Financing
7. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
8. Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
9. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
10. PLC Systems Secures $4 Million in Financing
11. Biomatrica Secures Strategic Investment from IQT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... founder of Spectrum Science Communications , announced today that ... two consecutive years of high double digit growth in fee revenues. ... assumed management of the firm that Seng founded in 1996. Earlier ... of the Year and was selected among the Best Places to ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... and characterization laboratories, is now offering HIAC particle counting and sizing services for ... , Gateway Analytical instituted the new service as a response to the needs ...
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... 'Tis ... can disrupt daily routines. That means it's also the season when eating healthy, staying ... living with diabetes) on schedule is harder to do. , "Shopping trips, parties ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD , ... arrival of the newest Sciton laser in January 2017. The Halo is the ... and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo ...
(Date:12/5/2016)... ... , ... Researchers at Johns Hopkins All Children’s Hospital want to learn more ... course of three years, researchers will study concussions and changes in brain function by ... special sensors, will track the location and force of the hit. The sensors store ...
Breaking Medicine News(10 mins):